Overview
Herve Lejeune practices in Bron, France. Mr. Lejeune is rated as an Experienced expert by MediFind in the treatment of Hypogonadotropic Hypogonadism. His top areas of expertise are Klinefelter Syndrome, Hypogonadism, Intersex, and Orchitis.
His clinical research consists of co-authoring 31 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hypogonadotropic Hypogonadism.
Locations
Lyon, France
Auvergny, France
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- HypogonadismMr. Lejeune isDistinguished. Learn about Hypogonadism.
- Klinefelter SyndromeMr. Lejeune isDistinguished. Learn about Klinefelter Syndrome.
- Advanced
- IntersexMr. Lejeune isAdvanced. Learn about Intersex.
- Experienced
- ADULT SyndromeMr. Lejeune isExperienced. Learn about ADULT Syndrome.
- Hypogonadotropic HypogonadismMr. Lejeune isExperienced. Learn about Hypogonadotropic Hypogonadism.
- Isolated Hypogonadotropic HypogonadismMr. Lejeune isExperienced. Learn about Isolated Hypogonadotropic Hypogonadism.
- Leydig Cell Testicular TumorMr. Lejeune isExperienced. Learn about Leydig Cell Testicular Tumor.
- OrchitisMr. Lejeune isExperienced. Learn about Orchitis.
- Sertoli-Leydig Cell TumorMr. Lejeune isExperienced. Learn about Sertoli-Leydig Cell Tumor.